Drug Updates

Recent Clinical Updates

Search and filter HCP Connect coverage by specialty, drug topic, reference, or clinical keyword.

Clinical Coverage

Search drug updates and clinical coverage.

12 loaded

Neurology

FDA Approves Efgartigimod for Myasthenia Gravis: New Treatment Algorithm for AChR Negative MuSK Negative Patients

Efgartigimod approved for myasthenia gravis: new treatment algorithm for AChR negative MuSK negative patients.

May 14|3 min read|Dr. Vikram Patel

Oncology

Liquid Biopsy for ESR1 Mutation Testing: Key Insights for Breast Cancer Management

Liquid biopsy for ESR1 mutation testing is crucial for managing ER+ breast cancer, guiding treatment decisions for patients.

May 14|3 min read|Dr. Meera Pillai

Cardiology

FDA Approves Semaglutide for HFpEF: 20% Reduction in Heart Failure Events

Semaglutide approved for HFpEF: 20% reduction in heart failure events. Key implications for clinicians.

May 14|3 min read|Dr. Arjun Sharma

Rheumatology

FDA Warns of Increased Cardiovascular and Cancer Risks with JAK Inhibitors in Rheumatoid Arthritis

FDA warns of increased cardiovascular and cancer risks with JAK inhibitors in rheumatoid arthritis, necessitating careful patient management.

May 14|3 min read|Dr. Deepak Nair

Neurology

FDA Approves Lecanemab for Alzheimer: 27% Cognitive Decline Reduction

FDA approves lecanemab for Alzheimer: 27% cognitive decline reduction in early-stage patients, highlighting new treatment options.

May 14|3 min read|Dr. Aditi Kulkarni

Pulmonology

Severe Asthma Biologics Comparison: Mepolizumab, Benralizumab, Dupilumab, Tezepelumab, and Depemokimab Insights for 2026

Explore the comparative efficacy of severe asthma biologics: mepolizumab, benralizumab, dupilumab, tezepelumab, and depemokimab insights for 2026.

May 14|2 min read|Dr. Nikhil Chatterjee

Dermatology

Atopic Dermatitis Biologics Comparison: Dupilumab, Tralokinumab, Lebrikizumab, and JAK Inhibitors

Atopic dermatitis biologics comparison: dupilumab, tralokinumab, lebrikizumab, and JAK inhibitors for effective treatment.

May 14|3 min read|Dr. Rohan Gupta

Cardiology

HFpEF Management 2026: SGLT2 Inhibitors and Spironolactone Show Mixed Results

HFpEF management updates: SGLT2 inhibitors show promise, while spironolactone lacks efficacy in recent trials.

May 14|3 min read|Dr. Kavya Sharma

Neurology

FDA Approves Lecanemab for Alzheimer: Biweekly IV vs Weekly Subcutaneous Administration

FDA approves lecanemab for Alzheimer: biweekly IV vs weekly subcutaneous administration options.

May 14|3 min read|Dr. Aditi Kulkarni

Cardiology

Baxdrostat Reduces Resistant Hypertension: Comparison with Spironolactone and Eplerenone

Baxdrostat reduces resistant hypertension: 12 mmHg blood pressure reduction compared to spironolactone and eplerenone.

May 14|3 min read|Dr. Kavya Sharma

Endocrinology

GLP-1 Receptor Agonists 2026: Comprehensive Comparison of Orforglipron, Tirzepatide, and Semaglutide

WHO guidelines update on GLP-1 receptor agonists: orforglipron, tirzepatide, semaglutide for obesity treatment.

May 14|3 min read|Dr. Amit Desai

Oncology

FDA Approves Vepdegestrant for ESR1-Mutated Breast Cancer: 5-Month PFS Improvement Over Fulvestrant

FDA approves vepdegestrant for ESR1-mutated breast cancer: 5-month PFS improvement over fulvestrant.

May 14|3 min read|Dr. Rahul Verma